$226.26
-5.09-2.2%
Dern. MÀJ: Nov 13, 11:57 AM
Moderna rose 826.9% from $24.96 to $231.35, ahead of the S&P 500's +12.7%. Its worst day was Aug 20 (−23.5%), and its low came Nov 20 at $22.36.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Moderna closed at its lowest level of the year, 10.4% below where the year started.
−7.5% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
EPS of $-2.11 beat the $-2.60 estimate on $678.0M revenue (est. $638.9M); FY revenue guidance of $2.1B against the $2.1B consensus.
+5.3% · S&P 500 +0.1%
EPS of $-1.18 beat the $-3.71 estimate on $389.0M revenue (est. $233.8M); FY revenue guidance of $2.1B against the $2.1B consensus.
−1.2% · S&P 500 +0.3%
EPS of $-1.97 beat the $-2.07 estimate on $145.0M revenue (est. $104.4M); FY revenue guidance of $2.1B against the $2.1B consensus.
−5.4% · S&P 500 +0.7%
Moderna shares rose 177.0%, while the S&P 500 rose 0.2%.
+177.0%, the year's best day, on 199M shares, the year's heaviest volume · S&P 500 +0.2%
EPS of $0.38 beat the $-1.22 estimate on $1.3B revenue (est. $889.9M); FY revenue guidance of $2.2B–$2.4B against the $2.1B consensus.
+5.3% · S&P 500 +0.3%
Where it ended: a close of $231.35 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 12, 2027 (EPS est. $-2.18, revenue est. $585.8M).
Nothing in the past 12 months.
All MRNA dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MRNA and SPY from Benzinga historical bars. Not investment advice.